Cellulitis is a serious bacterial skin infection that affects the subcutaneous tissues, often caused by Streptococcus or Staphylococcus bacteria. It presents as a rapidly spreading, painful, and swollen area, typically on the legs or face. The condition can range from mild to life-threatening, especially in immunocompromised individuals. Effective treatment involves antibiotics, but resistance patterns and atypical pathogens complicate management. This presentation explores the epidemiology, risk factors, diagnostic approaches, and evolving treatment strategies for cellulitis.
Epidemiology and Risk Factors
Most common bacterial skin infection, accounting for 59% of complicated skin and skin structure infections (cSSTIs)
Predominantly caused by Group A beta-hemolytic streptococci (GABHS) and Staphylococcus aureus, including MRSA
Risk factors include diabetes, venous insufficiency, lymphedema, and immunosuppression
Immunocompromised patients (e.g., cancer, transplant recipients) are at higher risk for atypical pathogens
Increasing antibiotic resistance complicates treatment, with MRSA rates steadily rising
Clinical Presentation and Diagnosis
Classic symptoms include erythema, warmth, swelling, and pain, often with systemic fever
Streptococcal infections spread rapidly, while staphylococcal infections are more localized
Diagnosis is clinical, but blood cultures and wound cultures may identify pathogens
Imaging (e.g., MRI) is rarely needed but may help in severe or recurrent cases
Differential diagnosis includes erysipelas, deep vein thrombosis, and necrotizing fasciitis
Treatment and Management
First-line antibiotics include penicillin, cephalosporins, or clindamycin for streptococcal infections
MRSA coverage (e.g., vancomycin, daptomycin) is essential if suspected or confirmed
Immunocompromised patients may require broader-spectrum antibiotics (e.g., antipseudomonal agents)
Severe cases may require hospitalization and intravenous therapy
Supportive care includes elevation, compression, and pain management
Cellulitis remains a significant clinical challenge due to its prevalence, varying severity, and evolving resistance patterns. Early recognition and appropriate antibiotic therapy are critical for successful outcomes. Immunocompromised patients require special consideration due to the risk of atypical infections. Ongoing research into resistance mechanisms and novel treatments will be essential in managing this condition effectively. Public health efforts to reduce antibiotic misuse and improve infection control are also vital in combating cellulitis.
